RELATED STUDY
A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX)
Key Findings: This study of patients with Fragile X syndrome found that a novel transdermal preparation of cannabidiol (ZYN002) was well tolerated and effective in reducing disruptive social behaviors in children and adolescents with ≥ 90% methylation of the promoter region of the FMR1 gene.
Type of Study: Double Blind Clinical Trial
Study Sample Size: 212
Study Result: Positive
Study Location(s): Australia, United States
Year of Pub: 2022
Cannabinoids Studied: Cannabidiol (CBD), Anandamide (AEA), 2-Arachidonoyl Glycerol (2-AG)
Phytocannabinoid Source: Unspecified
Chemotype: Chemotype III
Receptors Studied: CB1, CB2, GPCR
Ligands Studied: Dopamine, GABA, Serotonin
Dosage: ZYN002 (cannabidiol) - 250 mg or 500 mg transdermally, daily
Route of Administration: Topical
Link to study
